Effects on Haemostasis of Hormone Replacement Therapy with Transdermal Estradiol and Oral Sequential Medroxyprogesterone Acetate: A 1 -year, Double-blind, Placebo-controlled Study

Summary

After menopause the haemostatic balance shifts towards a latent hypercoagulable state. To evaluate the effects of two regimens of transdermal estradiol (E2) combined with progestin on the balance between procoagulant factors and inhibitors, 255 women in physiological menopause for 1-5 years were randomly allocated to 1 year of treatment with cyclic transdermal E2 (50 Μg/day for 21 days) plus medroxyprogesterone acetate (MPA) (10 mg/day from days 10 to 21), continuous transdermal E2 (50 Μg/day for 28 days) plus MPA (10 mg/day from days 14 to 25), or placebo. Fibrinogen, factor VII (FVII), factor VIII:C (FVIII:C), antithrombin III (ATIII), protein C, protein S, heparin cofactor II (HCII) and plasminogen activator inhibitor (PAI-1) levels were measured at baseline and after 6 and 12 cycles. 167 women who took the treatment for at least 6 cycles were evaluable. The continuous treatment group had significantly lower final values of fibrinogen, FVII, ATIII, protein S and HCII than the placebo group; the cyclic treatment reduced fibrinogen in comparison with placebo but the difference was not significant.

In conclusion, both regimens produce a clinically relevant decrease of fibrinogen levels; the continuous regimen affects also the levels of FVII and inhibitors suggesting that the haemostatic balance is shifted to a more physiological state.

• References

• 1 Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 (Β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-1106
• 2 Stampfer MJ, Coldizt GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63
• 3 Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-1109
• 4 Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-331
• 5 Cust MP. A risk-benefit assessment of estrogen therapy in postmenopausal women. Drug Safety 1990; 5: 345-358
• 6 Godsland IF, Walton C, Stevenson JC. Carbohydrate metabolism as a cardiovascular disease risk factor - its relation to menopause and hormone replacement therapy. In: Cardiovascular Disease and HRT New perspectives. Samsiae G. ed. Parthenon Publishing Group; Camforth, UK: 1992: 15-21
• 7 Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993; 70: 584-587
• 8 Meade TW, Haines AP, Imeson JD, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet 1983; i: 22-24
• 9 Scarabin PY, Bonithon-Kopp C, Bara L, Guize L, Samama MM. Relationship between plasminogen activator inhibitor activity and menopausal status. Fibrinolysis 1990; 4: 233-236
• 10 Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990; 74: 77-81
• 11 Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Herschman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biological effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620
• 12 Alkjaersig N, Fletcher AP, De Ziegler D, Steingold KA, Meldrum DR, Judd HL. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. J Lab Clin Med 1988; 111: 224-228
• 13 Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulaton factors in postmenopausal women. Thromb Res 1991; 62: 1-8
• 14 Fox J, George AJ, Newton JR, Parsons AD, Stuart GK, Stuart J, Sturdee DW. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993; 18: 55-64
• 15 Kroon U-B, Silfverstolpe G, Tengbom L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-423
• 16 Kupperman HS, Wetchler BB. Contemporary therapy of the menopausal syndrome. JAMA 1959; 171: 1627-1637
• 17 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 18 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-1186
• 19 Fleiss JL. The design and analysis of clinical experiments. Ed. John Wiley and Sons 1986
• 20 Ernst E. Fibrinogen: an important risk factor for atherothrombotic diseases. Ann Med 1994; 26: 15-22
• 21 The writing group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995 273. 199-208
• 22 Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Della Volpe A, Polli E. the PLAT Study Group. The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Arterioscler Thromb 1992; 12: 1063-1070
• 23 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537
• 24 Rapaport SI, Rao LVM. Thrombosis Council Distinguished Lecture: initiation and regulation of tissue factor-dependent blood coagulation. Arterisocler Thromb 1992; 12: 1111-1121
• 25 Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. the Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-1075
• 26 Lobo AA, Pickard JH, Wild RA, Walsh B, Hirvonen E. for the Menopause Study Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987-995
• 27 Meilhan E, Kuller LH, Kiss JE, Matthews KA, Lewis JH. Coagulation parameters among pre- and post-menopausal women. Am J Epidemiol 1988; 28: 908
• 28 Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet 1991; 338: 850-851
• 29 Cortellaro M. Antithrombin III and arterial disease. Lancet 1991; 338: 1525-1526
• 30 Conlan MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sorlie P, Wu KK. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemost 1994; 72: 551-556
• 31 Carr ME, Steingold KA, Zekert SL. ProteinS levels during the normal menstrual cycle and during estrogen therapy for premature ovarian failure. Am J Med Sci 1993; 306: 212-217